Speaking of Women’s Health Column
Menopause and Symptoms
Posted on October 31, 2017
Dr. Sabrina Sikka shares the top eight articles from 2017 that was discussed at this year's North American Menopause Society (NAMS) meeting.
Posted on September 11, 2017
Read menopause specialist Dr. Holly L. Thacker’s column on the newly released position statement from the North American Menopause Society about menopausal hormone therapy.
Posted on August 02, 2017
Read women’s health fellow, Dr. Anna Camille Moreno’s column on genitourinary syndrome of menopause or commonly known to us as vulvovaginal atrophy.
Posted on May 15, 2017
Please read Center for Specialized Women’s Health nurse Lillie McKinney’s guest column on menopause, aging and a new stage in life.
Posted on February 10, 2017
Read Dr. Thacker’s column on risk factors for early menopause and issues associated with premature menopause and surgical menopause.
Posted on December 05, 2016
Dr. Holly L. Thacker explains cold flashes and how they can affect women.
Posted on October 29, 2015
Drs. Elim Shih and Heather Foreman discuss the latest groundbreaking medical updates for women, including highlights from the 2015 National American Menopause Society meeting and Addyi, the first medication for women suffering from low sexual desire.
Posted on October 17, 2015
The medication, Addyi, is now available in select pharmacies by approved prescribers. Below is Dr. Holly L. Thacker's, Executive Director of Speaking of Women's Health, statement for the upcoming Innovation Summit where flibanserin is listed as one of the Top 10 Innovations of the year.
Posted on August 19, 2015
Read Dr. Holly L. Thacker’s column on the ‘hot topic’ of the recent approval of Flibanserin (Addyi) for the treatment of hypoactive sexual desire disorder (HSDD) for pre-menopausal women.
Posted on March 11, 2015
Read Dr. Michael Krychman, MD's column on female sexual empowerment. Dr. Krychman is an OB-GYN, sex therapist and leading women's sexual health expert. He has spoken out in favor of "Even the score" for women and sexual function therapies at the FDA level. The score is currently 26-0, which is 26 approved medicinal therapies for male sexual dysfunction and zero for women.